EVIO (EVIO) ROIC %: -8.84% (As of Jun. 2020)


What is EVIO ROIC %?

EVIO EVIO -98.00% ROIC % is -8.84% as of Jun. 2020.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. EVIO's annualized return on invested capital (ROIC %) for the quarter that ended in Jun. 2020 was -8.84%.

As of today (2026-06-25), EVIO's WACC % is 0.00%. EVIO's ROIC % is 0.00% (calculated using TTM income statement data). EVIO earns returns that do not match up to its cost of capital. It will destroy value as it grows.


EVIO  (OTCPK:EVIO) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, EVIO's WACC % is 0.00%. EVIO's ROIC % is 0.00% (calculated using TTM income statement data). EVIO earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


EVIO ROIC % Related Terms


EVIO ROIC % Historical Data

* Premium members only.

The historical data trend for EVIO's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EVIO ROIC % Chart

EVIO Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19
ROIC %
-140.22 -35.69 -33.32 -60.11 -43.40

EVIO Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.09 -51.61 -31.64 -45.47 -8.84

EVIO vs VCBD, ACCA, LITH: ROIC % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, EVIO's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EVIO ROIC % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EVIO's ROIC % distribution charts can be found below:

* The bar in red indicates where EVIO's ROIC % falls into.



EVIO ROIC % Calculation

EVIO's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Sep. 2019 is calculated as:

ROIC % (A: Sep. 2019 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Sep. 2018 ) + Invested Capital (A: Sep. 2019 ))/ count )
=-7.326 * ( 1 - 0% )/( (18.29 + 15.474)/ 2 )
=-7.326/16.882
=-43.40 %

where

EVIO's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Jun. 2020 is calculated as:

ROIC % (Q: Jun. 2020 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2020 ) + Invested Capital (Q: Jun. 2020 ))/ count )
=-1.224 * ( 1 - 0% )/( (14.121 + 13.571)/ 2 )
=-1.224/13.846
=-8.84 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2020) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -8.84% mean?
EVIO (EVIO) has a ROIC % of -8.84% as of Jun. 2020. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on EVIO and its competitors.
Is EVIO's ROIC % too high?
EVIO's current ROIC % is -8.84%.
How does EVIO's ROIC % compare to VCBD and ACCA?
EVIO's ROIC % of -8.84% can be compared against companies in the Drug Manufacturers industry. The industry median ROIC % is 4.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Drug Manufacturers company?
The median ROIC % among Drug Manufacturers companies is 4.44, based on 985 companies in the industry. Companies in the top quartile (top 25%) have a ROIC % significantly above this median, while those in the bottom quartile fall well below. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on EVIO and its competitors. For the Drug Manufacturers industry, the median ROIC % is 4.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EVIO's current ROIC % is -8.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EVIO stock overvalued right now?
EVIO (EVIO) has a current ROIC % of -8.84%. The current ROIC % is -8.84%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For EVIO (EVIO), the current ROIC % is -8.84% as of Jun. 2020. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EVIO Business Description

Address 2654 W. Horizon Ridge Drive Parkway, Suite B5-208, Henderson, NV, USA, 89052
EVIO Inc is a Colorado corporation and a diversified holding company. Its subsidiaries provide analytical testing and advisory services to the emerging legalized cannabis industry. The Company performs analytical testing for cannabis and cannabis-derived products, including hemp and CBD products. Its current operations also include pharmaceutical, environmental, stability, and analytical testing, as well as residential and commercial construction and investments, with operations in the United States and Canada.